Sriram Ryali Acquires 17,360 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Sriram Ryali bought 17,360 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were purchased at an average price of $1.42 per share, for a total transaction of $24,651.20. Following the purchase, the chief financial officer now owns 17,360 shares in the company, valued at $24,651.20. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Caribou Biosciences Trading Up 9.2 %

NASDAQ:CRBU opened at $1.43 on Friday. The business’s 50-day moving average is $1.77 and its 200 day moving average is $1.98. Caribou Biosciences, Inc. has a 12 month low of $1.30 and a 12 month high of $8.33. The company has a market capitalization of $129.49 million, a P/E ratio of -0.87 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.02 million for the quarter, compared to analysts’ expectations of $3.37 million. On average, research analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRBU has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a report on Friday, November 15th. Bank of America lowered their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Citigroup cut their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $10.33.

Hedge Funds Weigh In On Caribou Biosciences

Several institutional investors have recently bought and sold shares of the business. PFM Health Sciences LP increased its holdings in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock worth $8,441,000 after buying an additional 223,299 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Caribou Biosciences by 25.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after acquiring an additional 536,162 shares in the last quarter. Geode Capital Management LLC increased its stake in Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after acquiring an additional 124,782 shares during the last quarter. FMR LLC raised its position in Caribou Biosciences by 7.4% during the third quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after purchasing an additional 109,606 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Caribou Biosciences in the 2nd quarter valued at approximately $2,432,000. Institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.